As human tumors progress to advanced stages, one genetic alteration that occurs at high frequency is a loss of heterozygosity (LOH) at chromosome 10q23. Mapping of homozygous deletions on this chromosome led to the isolation of the PTEN gene, 
also designated MMAC1 (for mutated in multiple advanced  cancers)  and TEP1. This candidate tumor suppressor gene exhibits a high frequency of mutations in human glioblastomas and is also mutated in other cancers, including sporadic brain, breast, kidney and prostate cancers. PTEN has been associated with Cowden disease, an autosomal dominant cancer predisposition syndrome. The PTEN gene product  is a putative protein tyrosine phosphatase that is localized to the cytoplasm, and it shares extensive homology with the cytoskeletal proteins tensin and auxilin. Gene transfer studies have indicated that the phosphatase domain of PTEN is essential for growth suppression of glioma cells.
 

This Abmart monoclonal antibody is produced by immunizing mice with a synthetic  peptide (KLH-coupled) corresponding to carboxy-terminal  residues of  human PTEN.
 

PTEN (30G12) Mouse  mAb detects  endogenous  levels  of total  PTEN protein.
 

Store at -20°C, stable for one year from the date of shipment.
 

55kDa
 

Human, Mouse, Rat, Monkey, Chinese hamster, Dog
 

Mouse IgG2b
 

Use an anti-MOUSE secondary antibody to detect the 30G12 antibody.
 

Western blotting                         1:2000
Immunofluorescence                1:200
Immunohistochemistry             1:200